Navigation Links
Takeda to Acquire Nycomed
Date:5/18/2011

xpectations. We are proud to have contributed to Nycomed's development into a world-class pharmaceutical company with a strong market position and product pipeline. I feel confident that Takeda will be able to further build upon Nycomed's potential and create an even stronger company with a global market presence," said Kristoffer Melinder, Managing Partner of NC Advisory AB, advisor to the Nordic Capital funds.

1.  Expected benefits

  • Strong fit with Takeda’s sustainable growth strategy
  • Strengthens pan-European platform
  • Leverages Nycomed’s emerging markets strength to drive growth
  • Allows Takeda to maximize the value of its portfolio supported by enhanced development expertise and commercialization capability in Europe and emerging markets
  • Provides a significant growth driver with roflumilast (Daxas® tradename in Europe)
  • Immediate financial contribution(*)
  • More than 30% increase of annual revenue
  • More than 40% increase of operating income (excluding special factors derived from business acquisition)
  • More than 30% increase of EPS (excluding special factors derived from business acquisition)

  • (*) Comparison with the original outlook of fiscal 2013 in 2011-2013 Mid-Range Plan, announced on May 11, 2011

  • Complementary cultures and diverse talent pool

  • 2.  Acquisition summary (1)

    Acquiring company: Takeda Pharmaceutical Company Limited(2)

    Shareholders of Nycomed include Nordic Capital Funds V and VI, DLJ Merchant Banking Partners (a Credit Suisse affiliate), Coller International Partners IV and V, and Avista Capital Partners, Nycomed’s management and employees team(3)

    Number of outstanding shares: 13,778,110 shares (as of December 31, 2010)(4)

    Payment: Cash (Takeda will finance part of the transaction through a loan for about 600 to 700 billion yen)(5)

    Acquisition amount: &
    '/>"/>

    SOURCE Takeda Pharmaceutical Company Limited
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
    2. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
    3. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
    4. Takedas Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed
    5. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
    6. Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
    7. Takeda to Revise Timing of Alogliptin and Alogliptin/ACTOS MAA Filings in Europe
    8. Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes
    9. Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl)
    10. Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin, An Investigational Treatment for Type 2 Diabetes
    11. Takeda Receives FDA Complete Response Letter for the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/16/2014)... Tenn. , Sept. 16, 2014 A ... investigators has found the chemotherapy dose threshold below ... normal sperm production. The study appears in September 17 ... By clarifying which patients are at highest risk ... findings to eventually increase use of pre-treatment fertility preservation ...
    (Date:9/16/2014)... -- Chindex International, Inc. ("Chindex" or the "Company") (Nasdaq: ... meeting of stockholders held today, the Company,s stockholders adopted ... and among the Company, Healthy Harmony Holdings, L.P. ("Parent"), ... an affiliate of TPG, Shanghai Fosun Pharmaceutical (Group) Co., ... CEO of the Company. The Merger Agreement ...
    (Date:9/16/2014)... , Sept. 16, 2014 Research and Markets ... Vaccines Market 2014-2018" report to their offering. ... immunity of animals. Animal vaccines are generally prepared from weakened ... in their healthy state. Some of the animal vaccines are ... as protein subunits or toxic components. These ...
    Breaking Medicine Technology:Improved risk identification will aid fertility preservation in young male cancer patients 2Improved risk identification will aid fertility preservation in young male cancer patients 3Improved risk identification will aid fertility preservation in young male cancer patients 4Chindex Stockholders Approve Merger 2Chindex Stockholders Approve Merger 3Global Animal Vaccines Market 2014-2018: Key Vendors are Bayer, Elanco, Merck, Novartis, Sanofi and Zoetis 2Global Animal Vaccines Market 2014-2018: Key Vendors are Bayer, Elanco, Merck, Novartis, Sanofi and Zoetis 3
    ... BioStorage Technologies, Inc., a worldwide provider of long- and ... logistics, will expand its European operations with the opening ... full-service biorepository in Frankfurt, Germany. , BioStorage Technologies, expanded ... plan to accommodate a rapidly growing list of customers ...
    ... Oct. 21 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHMD) ... bavituximab in combination with docetaxel in patients with advanced breast ... planned treatment cycles in the Phase II study showed that ... the trial achieved an objective tumor response according to RECIST ...
    Cached Medicine Technology:BioStorage Technologies, Inc., Accelerates European Expansion with Opening of New German Facility 2Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast Cancer 2Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast Cancer 3Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast Cancer 4
    (Date:9/17/2014)... 17, 2014 ICS Learning Group, Inc. ... Excellence in Training for the Best Use of Games ... on an online operational safety training module that ICS ... operation. Using an approach that combined realistic 3D ... that was similar to a video game, including competition ...
    (Date:9/17/2014)... 2014 Health.Verticalize, a healthcare marketing company ... health insurance options in the 2014 open enrollment period, ... Moving forward Health Network will be using ... has intentionally remained out of the spotlight for the ... single website to its present position with dozens of ...
    (Date:9/16/2014)... Recently, BamboofloorChina.com, the popular online supplier ... of strand woven bamboo floors to its ... big promotion for the new items; the current discount ... is a great shopping season. Therefore, BamboofloorChina.com spares no ... new customers. All practical items offered by BamboofloorChina.com are ...
    (Date:9/16/2014)... UK report a poorer experience of care during pregnancy ... their care, suggests a new study published today (17 ... and Gynaecology ( BJOG ). , Differences in ... in many areas and have provided the focus for ... inequalities. , The Oxford University study, funded by the ...
    (Date:9/16/2014)... Holganix, an elite member of the Inc ... the country, produces an organic Bionutritional product that promotes ... decreasing disease and insect damage though significant root and ... hold its third annual Bionutritional Summit at the Seelbach ... 1:00 P.M. through 6:00 P.M., the day before the ...
    Breaking Medicine News(10 mins):Health News:ICS Learning Group Wins Gold in the 2014 Brandon Hall Excellence Competition for Best Use of Games and Simulations for Learning 2Health News:Health.Verticalize Rebrands as Health Network After Growing to 15 Million Users in Less Than One Year 2Health News:Health.Verticalize Rebrands as Health Network After Growing to 15 Million Users in Less Than One Year 3Health News:BamboofloorChina.com Announces Its Promotion For Strand Woven Bamboo Floors 2Health News:A greater focus on socially disadvantaged women is needed to improve maternity care in England 2Health News:Holganix Holds 3rd Annual Bionutrional Summit in Louisville, Kentucky 2
    ... Medical School in the South West of England have ... out of hours services in primary care are reluctant ... and carried out telephone interviews with 27 patients who ... practice cover in the evenings and weekends in England. ...
    ... WANTAGH, N.Y., Nov. 29 As family members age, ... performing daily,tasks, such as cooking and laundry. Some need ... professional medical care, and most,want to stay in the ... how to keep their parents safe, healthy and cared ...
    ... U.S. is caused by a form of bacteria, the ... It typically begins with a bulls-eye skin rash, accompanied ... If diagnosed early, Lyme can be treated successfully within ... Nearly 60 percent of patients who do not receive ...
    ... Appointed Worldwide Managing Partners, NEW YORK, Nov. ... the,largest fully integrated, global health marketing and communications ... the credit going to,its unique leadership team whose ... leadership, effective immediately, Doug Burcin and Donna,Murphy, Partners, ...
    ... -- There are estimated to be ... diagnosed with chronic Immune Thrombocytopenic Purpura (ITP), an ... platelets in their blood -- causing bruises, nosebleeds ... of an international multicenter clinical research study led ...
    ... Receives Failing Grades on Key Benchmarks, WASHINGTON, ... its first-ever state-specific Report,Card on Lung Cancer. The ... lethal disease by the state of Massachusetts. LCA-MA ... Lung cancer is the number one cause of ...
    Cached Medicine News:Health News:Out of hours doctors reluctant to do home visits, say patients 2Health News:Finding Ways for Seniors to Stay Safe, Healthy... and Home 2Health News:Finding Ways for Seniors to Stay Safe, Healthy... and Home 3Health News:Antibody responses in patients with Lyme arthritis 2Health News:Antibody responses in patients with Lyme arthritis 3Health News:World's Largest Fully Integrated, Global Health Marketing and Communications Group Appoints Global Leadership Team 2Health News:World's Largest Fully Integrated, Global Health Marketing and Communications Group Appoints Global Leadership Team 3Health News:Eltrombopag studied in Idiopathic Thrombocytopenic Purpura 2Health News:Lung Cancer Alliance-Massachusetts Issues Inaugural State-Specific Report Card on Lung Cancer 2
    ... The Accutest H. pylori WB ... for the qualitative detection of ... pylori in human whole blood. ... as an aid in the ...
    ... Rapid 5 minutes immunoassay, based on ... a monoclonal antibody, for the qualitative ... human stool. The Premier Platinum HpSA, ... after extensive evaluation, was accepted as ...
    Unitary one step immuno-chromatographic assay for the qualitative detection of infectious mononucleosis heterophile antibodies in human serum, plasma or whole blood....
    The NOW® Flu B test is the most frequently adopted rapid flu test on the market today. Testing could not be easier and the results are available in 15 minutes. Now you can focus on the results an...
    Medicine Products: